KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent Deferred Tax AssetsCurrent TaxesDividends payablesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsMinority InterestNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPensionPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Pfizer (PFE) Inventory (2016 - 2025)

Pfizer (PFE) has disclosed Inventory for 17 consecutive years, with $10.7 billion as the latest value for Q4 2025.

  • On a quarterly basis, Inventory fell 1.82% to $10.7 billion in Q4 2025 year-over-year; TTM through Dec 2025 was $10.7 billion, a 1.82% decrease, with the full-year FY2025 number at $10.7 billion, down 1.82% from a year prior.
  • Inventory was $10.7 billion for Q4 2025 at Pfizer, down from $11.5 billion in the prior quarter.
  • In the past five years, Inventory ranged from a high of $11.7 billion in Q3 2024 to a low of $8.5 billion in Q2 2021.
  • A 5-year average of $10.2 billion and a median of $10.3 billion in 2023 define the central range for Inventory.
  • Peak YoY movement for Inventory: fell 7.05% in 2021, then rose 17.5% in 2022.
  • Pfizer's Inventory stood at $9.1 billion in 2021, then decreased by 0.86% to $9.0 billion in 2022, then increased by 13.45% to $10.2 billion in 2023, then grew by 6.5% to $10.9 billion in 2024, then decreased by 1.82% to $10.7 billion in 2025.
  • Per Business Quant, the three most recent readings for PFE's Inventory are $10.7 billion (Q4 2025), $11.5 billion (Q3 2025), and $11.7 billion (Q2 2025).